-
COVER STORY
Nitto Avecia
Pre-Validation through PPQ
-
OLIGOS & PEPTIDES
Peptide therapeutics market: forecast and analysis 2015-2025
S. Ghosh
-
OLIGOS & PEPTIDES
Targeted delivery of nucleic acids via carbohydrate-protein interactions
A. S. Campbell
-
OLIGOS & PEPTIDES
Preparation of trinucleotide synthons for the synthesis of gene libraries
R. Raetz, B. Appel, S. Müller
-
PRODUCT FOCUS
CordenPharma
Drug Conjugation > How technology drives the supply chain
-
OVERVIEW ON PEPTIDES
AN INTRODUCTION:
B. H. Morimoto
Highlights on recent peptide achievements
-
OVERVIEW ON PEPTIDES
Hydrocarbon stapled peptides
W. D. Bennett
-
OVERVIEW ON PEPTIDES
Significant recent eventsin peptide pharmaceuticals: enfuvirtide
G. W. Erickson
-
OVERVIEW ON PEPTIDES
Peptides as targeting agents in nano-architectures for drug delivery
C. Gothard
-
OVERVIEW ON PEPTIDES
Accurate peptide quantification supports the transfer of MS-based quantitative proteomics to the clinic
V. Mainfroid
-
OVERVIEW ON PEPTIDES
Recent peptide research milestones and achievements
M. W. Pennington
-
OVERVIEW ON PEPTIDES
The most outstanding peptide achievement in the last two years
A. Pessi
-
OVERVIEW ON PEPTIDES
The use of QbD for peptide manufacturing processes
A. Tsirk, J. H. Rasmussen
-
OVERVIEW ON PEPTIDES
Recent advances in peptide drug discovery and development; a Key-role for peptide synthesis technology
J. Cain
-
OVERVIEW ON PEPTIDES
Small peptides for inhibition of central component of immunity: the complement system
D. El Mehdi, P. Deschatelets
-
OVERVIEW ON OLIGOS
AN INTRODUCTION:
K. L. Ackley
Are we there yet?
An update on oligonucleotide drug development
-
OVERVIEW ON OLIGOS
Recent achievements in therapeutic oligonucleotide chemistry
A. Laikhter
-
OVERVIEW ON OLIGOS
Clinical development of the toll-like receptor 9 agonist DIMS0150 in chronic active ulcerative colitis patients
T. Knittel
